1. Home
  2. Welcome Going Digital Attendees! Thank You

Welcome Going Digital Attendees! Thank You

Thanks for stopping by to learn more about the GeneSight® test!

We’re proud to be a platinum sponsor of the Going Digital: Behavioral Health Tech 2022 conference. As the category-leading pharmacogenomic test in mental health, the GeneSight test can help inform clinicians about how a patient’s genes may impact how the patient metabolizes and/or responds to certain mental health medications. The GeneSight test provides information about patients that may help clinicians avoid multiple medication trials.

GeneSight at Home

For some patients suffering from depression, anxiety or other psychiatric conditions, it can be a struggle just to leave the house. For some providers, the percentage of patients they see in-office is dropping in favor of virtual visits. These variables have made it challenging to complete pharmacogenomic testing that was historically conducted entirely in an office setting. That’s why we created GeneSight at Home – patients can take the test from the comfort of their home.

The GeneSight test

The GeneSight Psychotropic test identifies a patient’s genetic variations that may impact how they metabolize or respond to certain medications commonly prescribed to treat depression, anxiety, ADHD and other psychiatric conditions.

The GeneSight Psychotropic report:

  • Shows whether there are gene-drug interactions for 64 FDA-approved medications including antidepressants, anxiolytics, hypnotics, antipsychotics, stimulants and non-stimulants; to see a list of medications, visit genesight.com/product
  • Details the individual’s genotypes and phenotypes for 5 pharmacodynamic genes and 9 pharmacokinetic genes. COMT has been included for informational purposes

The GeneSight Difference

GeneSight’s Combinatorial Approach

An analysis published in the peer-reviewed Psychiatry Research shows the combinatorial approach used by GeneSight exceeds the effectiveness of single-gene testing at predicting sertraline metabolism in patients with major depressive disorder (MDD). Selective serotonin reuptake inhibitors (SSRIs) are often utilized as the first-line treatment for depression1,2 because they are generally well tolerated; sertraline, in particular, is recognized to have high efficacy and tolerability.3

This is the third study published in Psychiatry Research evaluating the combinatorial approach of the GeneSight test as compared to single-gene testing:

  • February 2021 – demonstrating the superior ability of combinatorial pharmacogenomic testing to predict variation in medication blood levels may result in improved patient outcomes
  • May 2020 – demonstrating how the combinatorial approach was better at predicting citalopram and escitalopram blood concentrations when compared to single-gene testing

Learn more about the algorithm: https://genesight.com/genetic-insights/understanding-the-genesight-test-algorithm/

Interested in partnering with GeneSight?

Thank you for your submission.

Someone will get in touch with you soon!

1,500,000+ people have taken the GeneSight test

7 clinical studies published in peer-reviewed journals. GeneSight Psychotropic is the only psychiatric pharmacogenomic test backed by such extensive research.

95% of patients pay $330 or less for their GeneSight test

Read More

New Updates to the Psychotropic Test

Myriad Genetics achieves HITRUST certified status for GeneSight

The GeneSight Mental Health Monitor

Patient Stories

Provider Stories